EUVIMEDEUVIMED entdecken
Open Access

Aberrant centrosome biogenesis disrupts nephron and collecting duct progenitor growth and fate resulting in fibrocystic kidney disease

Tao Cheng, Chidera Agwu, Kyuhwan Shim, Baolin Wang, Sanjay Jain iD, Moe R Mahjoub iD

Development · 15.12.2023 · 150 (24)

DOI: 10.1242/dev.201976 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Development, online erschienen am 21.12.2023. Verfasst von Tao Cheng und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Nephrology, Washington University in St Louis, St. Louis, MO 63110, USA. Hauptthemen laut MEDLINE: Kidney, Polycystic Kidney Diseases. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 92 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, NIGMS NIH HHS, National Institute of General Medical Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mutations that disrupt centrosome biogenesis or function cause congenital kidney developmental defects and fibrocystic pathologies. Yet how centrosome dysfunction results in the kidney disease phenotypes remains unknown. Here, we examined the consequences of conditional knockout of the ciliopathy gene Cep120, essential for centrosome duplication, in the nephron and collecting duct progenitor niches of the mouse embryonic kidney. Cep120 loss led to reduced abundance of both cap mesenchyme and ureteric bud populations, due to a combination of delayed mitosis, increased apoptosis and premature differentiation of progenitor cells. These defects resulted in dysplastic kidneys at birth, which rapidly formed cysts, displayed increased interstitial fibrosis and decline in kidney function. RNA sequencing of embryonic and postnatal kidneys from Cep120-null mice identified changes in the pathways essential for development, fibrosis and cystogenesis. Our study defines the cellular and developmental defects caused by centrosome dysfunction during kidney morphogenesis and identifies new therapeutic targets for patients with renal centrosomopathies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

KidneyPolycystic Kidney DiseasesCentrosomeHumansCell Cycle ProteinsMiceNephronsMice, KnockoutAnimalsFibrosis

Stichwörter der Autor:innen

Cell fateCentrioleCentrosomeCiliaCystic kidney diseaseFibrosisMouse

Substanzen

Cep120 protein, mouseCell Cycle Proteins

Autor:innen und Institutionen

  • Department of Medicine, Division of Nephrology, Washington University in St Louis, St. Louis, MO 63110, USA.
  • Department of Genetic Medicine, Weill Medical College of Cornell University, New York, NY 10065, USA.
  • Department of Cell Biology and Physiology, Washington University in St Louis, St. Louis, MO 63110, USA.

ORCID-Profile: Sanjay Jain, Moe R Mahjoub

Förderung

  • NIDDK NIH HHS
  • NIGMS NIH HHS
  • National Institute of General Medical Sciences
  • National Institute of Diabetes and Digestive and Kidney Diseases

Zitieren

APA

Cheng, T., Agwu, C., Shim, K., Wang, B., Jain, S., & Mahjoub, M. R. (2023). Aberrant centrosome biogenesis disrupts nephron and collecting duct progenitor growth and fate resulting in fibrocystic kidney disease. Development, 150(24). https://doi.org/10.1242/dev.201976

Vancouver

Cheng T, Agwu C, Shim K, Wang B, Jain S, Mahjoub MR. Aberrant centrosome biogenesis disrupts nephron and collecting duct progenitor growth and fate resulting in fibrocystic kidney disease. Development. 2023;150(24). doi:10.1242/dev.201976

BibTeX
@article{Cheng2023,
  author = {Cheng, Tao and Agwu, Chidera and Shim, Kyuhwan and Wang, Baolin and Jain, Sanjay and Mahjoub, Moe R},
  title = {Aberrant centrosome biogenesis disrupts nephron and collecting duct progenitor growth and fate resulting in fibrocystic kidney disease},
  journal = {Development},
  year = {2023},
  volume = {150},
  number = {24},
  doi = {10.1242/dev.201976}
}
Kostenlos starten →